Research programme: staphylococcus aureus vaccine - Astellas Pharma/Boston Children's Hospital/ClearPath Development Company

Drug Profile

Research programme: staphylococcus aureus vaccine - Astellas Pharma/Boston Children's Hospital/ClearPath Development Company

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma; ClearPath Development Company
  • Developer Astellas Pharma; Boston Childrens Hospital; ClearPath Development Company
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Staphylococcal infections

Most Recent Events

  • 19 Dec 2017 ClearPath Development Company, under strategic partnership with Astellas Pharma, agrees to co-develop Staphylococcus aureus vaccine with Boston Children's Hospital
  • 19 Dec 2017 Early research in Staphylococcal infections (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top